Putting Prevention into Practice
Adult Immunization—Influenza Vaccine
Am Fam Physician. 2000 May 1;61(9):2901-2902.
DB is 72 years old and recently moved into a nursing home. She has not received her yearly influenza shot. DB has numerous health problems, including diabetes mellitus, arthritis (for which she receives prednisone) and emphysema. She has a history of having influenza almost every year for the past 15 years.
Which of the following factors contribute to placing this patient at high risk for serious complications of influenza?
A. More than 65 years of age.
B. Living in an institution.
C. Having pulmonary lung disease.
D. Having a history of influenza viruses.
Shortly after DB moved to the nursing home, an outbreak of influenza occurred.
Amantadine and rimantadine would be indicated for DB for which one of the following reasons?
A. Treatment following exposure to influenza A.
B. Treatment following exposure to influenza B.
C. Prophylaxis following exposure to influenza A.
D. Prophylaxis following exposure to influenza B.
E. Prophylaxis following exposure to either influenza A or B.
During which one of the following times would it have been optimal for DB to have received the influenza vaccine?
A. Once influenza virus activity has been documented in the community.
B. During the month of September.
C. Between October and mid-November.
D. Between December and mid-January.
E. Between September and January.
Which of the following statements about influenza vaccination is/are correct?
A. The influenza vaccine can be given concurrently with the pneumococcal vaccine.
B. The presence of minor illness, with or without fever, is a contraindication to use of the influenza vaccine.
C. The influenza vaccine cannot cause influenza.
D. It is important not to give vaccines too early in the influenza season.
1. The answers are A, B and C: her age, her residency in an institution and her chronic medical problems. Elderly persons and persons six months of age or older who are residents of chronic care facilities or who have certain chronic medical disorders (including cardiac, respiratory, renal or immunologic problems, hemoglobinopathies and diabetes) are at an increased risk for complications from influenza infection. Health care workers infected with influenza represent a potential vector for spread to high-risk patients. More than 90 percent of the deaths attributed to pneumonia and influenza in epidemics occur among persons 65 years of age and older.1 Influenza is estimated to cause a yearly average of 4.1 to 4.4 million excess respiratory illnesses and 16.6 to 17.9 million excess bed and restricted activity days in persons 20 years of age or older.2
Influenza infection can result in considerable morbidity and mortality. A study of influenza vaccination among community-dwelling elderly persons reported reductions of 48 to 57 percent for hospitalizations because of pneumonia and influenza, and reductions of 27 to 39 percent for all acute and chronic respiratory conditions.3 Reductions in morbidity, hospitalizations and mortality have also been reported in observational studies.
2. The answer is C: prophylaxis following exposure to influenza A. Amantadine and rimantadine are effective only against influenza A when used prophylactically in healthy community-living or institutionalized persons. Effectiveness is estimated to be 70 to 90 percent.4-6 Neither drug is effective for influenza B, so it is important to be knowledgeable about the likely type of influenza pathogen within the community. Either drug (200 mg per day) should be started at the time of influenza vaccination and continued for 14 days. Amantadine can also be used in unimmunized persons to enhance protection among those who may have a poor antibody response, or among those in whom the vaccine is contraindicated.
3. The answer is C: between October and mid-November. Because the influenza season in the United States usually begins in December, the period between October and mid-November usually is the optimal time for immunization campaigns. However, health care professionals should take advantage of the opportunity to begin immunizing all high-risk patients, including older adults, who are seen for health care beginning in September. Immunization programs may begin as soon as the current vaccine is available if regional influenza activity is expected to begin earlier than December. Immunization should be offered up to and even after the time that influenza virus activity is documented in a community. In some years, this activity may occur as late as April.
4. The answers are A, C and D: the influenza vaccine can be given concurrently with the pneumococcal vaccine; the influenza vaccine cannot cause influenza; and it is important not to give vaccines too early in the influenza season. The presence of minor illness, with or without fever, is not a contraindication to use of the influenza vaccine. However, adults with acute febrile illness should not be vaccinated until their symptoms have abated. The influenza vaccine should be given shortly before the onset of the influenza season. Because antibody levels decline with time, immunizations should not be given too early in the influenza season.
REFERENCESshow all references
1. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 1995;44(RR-3):1–22....
2. Sullivan KM, Monto AS, Longini IM Jr. Estimates of the US health impact of influenza. Am J Public Health. 1993;83:1712–6.
3. Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med. 1994;331:778–84.
4. Dolin R, Reichman RC, Madore HP, Maynard R, Linton PN, Webber-Jones J. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med. 1982;307:580–4.
5. Monto AS, Gunn RA, Bandyk MG, King CL. Prevention of Russian influenza by amantadine. JAMA. 1979;241:1003–7.
6. Nafta I, Turcanu AG, Braun I, Companetz W, Simionescu A, Birt E, et al. Administration of amantadine for the prevention of Hong Kong influenza. Bull World Health Organ. 1970;42(3):423–7.
The case studies and answers to the following questions on administering the pneumococcal vaccine are based on the 1996 recommendations of the United States Preventive Services Task Force (USPSTF), part of the Put Prevention into Practice program of the Agency for Healthcare Research and Quality (AHRQ), formerly the Agency for Health Care Policy and Research. The answers appear on the following page. The evidence on the efficacy of the pneumococcal vaccine and other USPSTF topics will be reviewed over the next four years; therefore, some of the recommendations may change.
The 1996 recommendations and other information are contained in the “Guide to Clinical Preventive Services,” 2d ed, chapter 66: Adult Immunizations. For more information, also consult the “Clinicians Handbook of Preventive Services,” 2d ed, chapter 50: Pneumococcus. The guide and handbook can be viewed on the Web site of the AHRQ at http://www.ahrq.gov/clinic. Specific journal references cited in the answers are provided in the discussion.
Copyright © 2000 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions
More in AFP
MOST RECENT ISSUE
Jan 15, 2019
Access the latest issue of American Family Physician